Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome

Abstract

Objective:The established link between oestrogen and breast cancer occurs via both oestrogen receptor (ER)-mediated and non ER-mediated mechanisms. The term genotoxic estrogens describes mutagenic metabolites, including oestrogen catechols and quinones, which have been linked to breast carcinogenesis in post-menopausal women. We aimed to assess whether the route of administration of 17β oestradiol (E 2 ) affects the accumulation of genotoxic oestrogen metabolites in a model of ovarian failure in young girls with Turner syndrome.Methods: Stored plasma samples obtained at 0 and 12 months were used from 40 adolescents with Turner syndrome who participated in a 12 months randomized controlled trial of the metabolic impact of E 2 orally (2 mg/d) vs transdermally (100 µg/d);dose escalation allowed matching of unconjugated E 2 levels in the parent study. We measured 12 oestrogen metabolites (total concentrations = conjugated and unconjugated) using a highly sensitive LCMSMS assay. Results from 48 normally menstruating adolescents were used for comparison. Results: After treatment, least square mean (SE) total E 2 concentrations were higher in the oral vs transdermal group (6784 pmol/L vs 1123 [1614], P < 0.0001), as was oestrone (E 1 ) (91 060 pmol/L vs 19 278 [16 534], P < 0.0001). Also, higher after oral treatment were catechol-oestrogens 4-hydroxy-E 2 (149 vs 28 [±49] pmol/L), 2-hydroxy-E 2 (300 vs 76 [±52]), 4-hydroxy-E 1 (450 vs 105 [±113]), 2-hydroxy-E 1 (3094 vs 740 [±684]) and 16α-hydroxy-E 1 (3,007 vs 157 [±534]) (<0.001 between groups). Levels were much closer to controls in the transdermal group. Conclusions: Common feminizing doses of oral oestradiol for 12 months result in substantial accumulation of unphysiologic, genotoxic oestrogens compared to transdermal oestradiol, expanding concerns about oral oestrogens' first hepatic passage.Further studies assessing long-term risks of these metabolites in women taking different forms of oestrogen are needed. K E Y W O R D Sbreast cancer, children, genotoxic oestrogens, LCMSMS assay, oestradiol, transdermal, Turner syndrome

Ultra-low-dose estrogen therapy for female hypogonadism

“…First, our estradiol assay sensitivity was 5 pg/mL, and endogenous estrogen during the early pubertal period cannot be detected. In the future, when an advanced technology such as liquid chromatography-tandem-mass spectrometry technique is more easily accessible, estradiol can be measured before and after initiating replacement therapy (8). Second, our estradiol assay failed to cross-react with EE2.…”

Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition

“…The transdermal route is more physiological in the form of 17β-estradiol, which avoids first-pass liver metabolism. Additionally, it has fewer risks and may be the safest option in patients with a history of DVT ( 62 , 63 , 64 ). There is evidence to suggest that it leads to better outcomes for bone density and uterine development ( 63 ).…”

“…There is evidence to suggest that it leads to better outcomes for bone density and uterine development ( 63 ). Concentrations of genotoxic estrogens are also lower with this route ( 64 ) and there is no evidence to suggest an increase in breast cancer for young women on estrogen replacement. When puberty is being induced, the dosage is gradually increased over a period of 24 months.…”

The Biology of Breast Cancer Disparities in Hispanics: Current Knowledge, Gaps, and Research Opportunities

“…Measurements of total estradiol and its metabolites after 12 months of therapy were obtained. The oral estradiol group was associated with higher generation of genotoxic estrogen metabolites than normal post-pubertal girls and the transdermal estradiol group [16]. This may explain the higher risks of breast cancer associated with oral hormonal contraception reported by Morch et al [15] and suggests that a switch from oral estrogen to transdermal estrogen contraception could potentially decrease breast cancer and ameliorate breast cancer disparities.…”